EDITAS MEDICINE, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
EDITAS MEDICINE, INC. (EDIT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- EDITAS MEDICINE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.19M, a 17.68% decline year-over-year.
- EDITAS MEDICINE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.10M, a 29.44% decline year-over-year.
- EDITAS MEDICINE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.23M, a 53.60% decline year-over-year.
- EDITAS MEDICINE, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.66M, a 46.83% decline year-over-year.
- EDITAS MEDICINE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.00M, a 53.31% decline from fiscal 2024.
- EDITAS MEDICINE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $21.42M, a 8.18% increase from fiscal 2023.
- EDITAS MEDICINE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $19.80M, a 32.42% decline from fiscal 2022.
- EDITAS MEDICINE, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $29.29M, a 32.50% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.19M 10-Q · filed 2026-08-05 | $4.29M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $2.10M 10-Q · filed 2026-08-05 | |||||
| 2025-12-31 | $10.00M 10-K · filed 2026-03-09 | |||||
| 2025-09-30 | $2.23M 10-Q · filed 2025-11-10 | $4.89M derived: sum of 2 quarters · filed 2026-08-05 | $7.87M derived: sum of 3 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $2.66M 10-Q · filed 2026-08-05 | $5.64M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $2.98M 10-Q · filed 2026-08-05 | |||||
| 2024-12-31 | $21.42M 10-K · filed 2026-03-09 | |||||
| 2024-09-30 | $4.80M 10-Q · filed 2025-11-10 | $9.81M derived: sum of 2 quarters · filed 2025-11-10 | $17.40M derived: sum of 3 quarters · filed 2025-11-10 | |||
| 2024-06-30 | $5.01M 10-Q · filed 2025-11-10 | $12.60M derived: sum of 2 quarters · filed 2025-11-10 | ||||
| 2024-03-31 | $7.58M 10-Q · filed 2025-11-10 | |||||
| 2023-12-31 | $19.80M 10-K · filed 2025-03-05 | |||||
| 2023-09-30 | $4.73M 10-Q · filed 2024-11-04 | $9.95M derived: sum of 2 quarters · filed 2024-11-04 | $14.45M derived: sum of 3 quarters · filed 2024-11-04 | |||
| 2023-06-30 | $5.21M 10-Q · filed 2024-11-04 | $9.72M derived: sum of 2 quarters · filed 2024-11-04 | ||||
| 2023-03-31 | $4.51M 10-Q · filed 2024-11-04 | |||||
| 2022-12-31 | $29.29M 10-K · filed 2025-03-05 | |||||
| 2022-09-30 | $5.88M 10-Q · filed 2023-11-03 | $12.50M derived: sum of 2 quarters · filed 2023-11-03 | $23.93M derived: sum of 3 quarters · filed 2023-11-03 | |||
| 2022-06-30 | $6.62M 10-Q · filed 2023-11-03 | $18.05M derived: sum of 2 quarters · filed 2023-11-03 | ||||
| 2022-03-31 | $11.43M 10-Q · filed 2023-11-03 | |||||
| 2021-12-31 | $43.40M 10-K · filed 2024-02-28 | |||||
| 2021-09-30 | $10.01M 10-Q · filed 2022-11-02 | $23.54M derived: sum of 2 quarters · filed 2022-11-02 | $35.74M derived: sum of 3 quarters · filed 2022-11-02 | |||
| 2021-06-30 | $13.53M 10-Q · filed 2022-11-02 | $25.73M derived: sum of 2 quarters · filed 2022-11-02 | ||||
| 2021-03-31 | $12.20M 10-Q · filed 2022-11-02 | |||||
| 2020-12-31 | $23.16M 10-K · filed 2023-02-22 | |||||
| 2020-09-30 | $5.84M 10-Q · filed 2021-11-09 | $11.26M derived: sum of 2 quarters · filed 2021-11-09 | $17.48M derived: sum of 3 quarters · filed 2021-11-09 | |||
| 2020-06-30 | $5.42M 10-Q · filed 2021-11-09 | $11.64M derived: sum of 2 quarters · filed 2021-11-09 | ||||
| 2020-03-31 | $6.22M 10-Q · filed 2021-11-09 | |||||
| 2019-12-31 | $27.24M 10-K · filed 2022-02-24 | |||||
| 2019-09-30 | $6.56M 10-Q · filed 2020-11-06 | $12.64M derived: sum of 2 quarters · filed 2020-11-06 | $20.50M derived: sum of 3 quarters · filed 2020-11-06 | |||
| 2019-06-30 | $6.08M 10-Q · filed 2020-11-06 | $13.94M derived: sum of 2 quarters · filed 2020-11-06 | ||||
| 2019-03-31 | $7.86M 10-Q · filed 2020-11-06 | $7.45M 10-Q · filed 2019-05-08 | ||||
| 2018-12-31 | $26.60M 10-K · filed 2021-02-26 | $24.18M 10-K · filed 2019-03-01 | ||||
| 2018-09-30 | $6.70M 10-Q · filed 2019-11-12 | $13.72M derived: sum of 2 quarters · filed 2019-11-12 | $20.25M derived: sum of 3 quarters · filed 2019-11-12 | |||
| 2018-06-30 | $7.03M 10-Q · filed 2019-11-12 | $6.35M 10-Q · filed 2019-08-07 | $13.56M derived: sum of 2 quarters · filed 2019-11-12 | |||
| 2018-03-31 | $6.53M 10-Q · filed 2019-11-12 | $5.88M 10-Q · filed 2019-05-08 | ||||
| 2017-12-31 | $15.29M 10-K · filed 2020-02-26 | |||||
| 2016-12-31 | $8.57M 10-K · filed 2019-03-01 | |||||
| 2015-12-31 | $1.17M 10-K · filed 2018-03-08 | |||||
| 2014-12-31 | $7.00K 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |